Fibrin-human umbilical cord mesenchymal stem cell conditioned medium gel and its preparation method and application
By developing fibrin-human umbilical cord mesenchymal stem cell conditioned culture medium gel, the problem of unsatisfactory uterine adhesion treatment and the risk of immunity and infection in the prior art is solved, and an effective treatment plan for moderate and severe patients is provided. Significantly improves treatment effectiveness and reduces risks.
Patent Information
- Application Number
- CN202211024647.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-08-25
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2042-08-25
AI Technical Summary
The treatment effect of the prior art for the treatment of uterine adhesions is not ideal, its application is limited, and there is a risk of immunity and infection, especially for moderate and severe patients.
Develop a fibrinogen-human umbilical cord mesenchymal stem cell conditioned culture medium gel, which forms a gel by mixing fibrinogen, thrombin, aprotinin and human umbilical cord mesenchymal stem cell conditioned culture medium at room temperature. In the treatment of uterine adhesions, it reduces the risk of stem cell therapy.
It significantly improves the therapeutic effect of uterine adhesions, especially in moderate and severe patients, reduces the risk of immunity and infection, and provides a new treatment plan. Fibrin and thrombin form a gel under CaCl2 cross-linking, supports stem cell growth and enhances The therapeutic effect.
Smart Images

Figure BDA0003815045150000041 
Figure BDA0003815045150000061 
Figure HDA0003815045160000011
Abstract
Description
Technical Field
[0001] The invention relates to the field of medical technology, in particular to a fibrin-human umbilical cord mesenchymal stem cell conditioned culture fluid gel and a preparation method and application thereof. Background Art
[0002] Intrauterine adhesions (IUA) are common gynecological diseases that seriously endanger female reproductive function and have poor treatment effects. The main cause of IUA is damage to the basal layer of the endometrium, which causes endometrial fibrosis and adhesions of the uterine wall or cervical canal. The main clinical manifestations are decreased menstrual volume, recurrent miscarriage, and infertility. The incidence of IUA in my country is high, and it is increasing with the increase in intrauterine surgery. It has become the primary cause of female uterine factor infertility.
[0003] The main treatment for IUA is hysteroscopic transcervical resection of adhesion (TCRA). After the operation, a physical barrier is placed to prevent re-adhesion, and oral estrogen is taken to promote endometrial repair. Patients with mild and moderate IUA can achieve certain therapeutic effects, but the treatment effect is poor for patients with severe IUA, and the re-adhesion rate after surgery is as high as 62.5%.
[0004] At present, the preparations commonly used to treat intrauterine adhesions are mainly biological preparations such as sodium hyaluronate, chitosan and collagen. Although most of them have been used in clinical practice, these preparations mainly work through physical barriers and biological effects, with limited repair effects, and are only auxiliary treatment measures after surgery. There is a phase I clinical study on the use of umbilical cord-derived mesenchymal stem cells (UCMSCs) combined with collagen membranes to treat intrauterine adhesions, but due to many limitations in the use of stem cell preparations, it has not been widely used in clinical practice.
[0005] Another type of research is the application of stem cells and their related preparations (exosomes and whole cell culture fluid) in the repair and reconstruction of the endometrium in IUA. Studies have shown that UCMSCs are effective in treating intrauterine adhesions, and a biological company has been approved for production of medical UCMSCs; however, stem cells are cell therapies, and the potential risks of immunity and infection increase, which limits their widespread application, and the research direction is focused on stem cell derivatives. A number of basic experiments and clinical studies have confirmed that UCMSCs derivatives, such as conditioned medium (CM) and exosomes (EXO), can repair the endometrium and inhibit fibrosis, and are potential treatment options for moderate to severe intrauterine adhesions.
[0006] Fibrinogen, also known as coagulation factor I, is a plasma protein. Under physiological conditions, fibrinogen and thrombin participate in the body's hemostasis, coagulation, wound healing and tissue repair processes. At present, fibrin-related products such as fibrin glue and fibrin hemostatic agents have been widely used in clinical practice, but have not been used in the treatment of intrauterine adhesions. Therefore, it is of great significance to develop a new preparation for the treatment of intrauterine adhesions, reduce the immune and infection risks of stem cell therapy, and provide a good treatment plan for patients with moderate and severe intrauterine adhesions. Summary of the invention
[0007] The purpose of the present invention is to provide a fibrin-human umbilical cord mesenchymal stem cell conditioned medium gel and a preparation method and application thereof, so as to solve the problems of unsatisfactory treatment effect, limited application and high risk of immunity and infection in the prior art.
[0008] The object of the present invention is achieved by: a fibrin-human umbilical cord mesenchymal stem cell conditioned medium gel, which comprises the following components:
[0009] Fibrinogen 8-12 mg / mL, thrombin 1-5 U / mL, aprotinin 50-250 μg / mL, CaCl 2 30-50mmol / L, human umbilical cord mesenchymal stem cell conditioned medium 0.30-0.40mL / mL.
[0010] The gel preferably comprises the following components: fibrinogen 10 mg / mL, thrombin 1-5 U / mL, aprotinin 50-250 μg / mL, CaCl 2 40mmol / L, human umbilical cord mesenchymal stem cell conditioned medium 0.30-0.40mL / mL.
[0011] The human umbilical cord mesenchymal stem cell conditioned medium is a medium containing 2×10 5 ~8×10 5 The conditioned medium was obtained by culturing for 46-50 hours with a number of cells / mL.
[0012] The culture medium used was: S&XFM mesenchymal stem cell serum-free medium.
[0013] A method for preparing a fibrin-human umbilical cord mesenchymal stem cell conditioned medium gel, comprising mixing human umbilical cord mesenchymal stem cell conditioned medium, thrombin, aprotinin and CaCl at room temperature. 2Mix evenly to make liquid A, and use fibrinogen solution as liquid B. Liquid A and liquid B are packaged separately, and the final concentrations of each component after mixing liquid A and liquid B are: fibrinogen 8-12 mg / mL, thrombin 1-5 U / mL, aprotinin 50-250 μg / mL, CaCl 2 30-50mmol / L, human umbilical cord mesenchymal stem cell conditioned medium 0.30-0.40mL / mL.
[0014] The human umbilical cord mesenchymal stem cell conditioned medium is a medium containing 2×10 5 ~8×10 5 The conditioned culture fluid was obtained by culturing for 46-50 hours with a number of cells / mL.
[0015] The use of the above gel in preparing a preparation for treating intrauterine adhesions.
[0016] The invention is simple to prepare and has good therapeutic effect, and provides a new treatment plan for patients with intrauterine adhesions, especially moderate and severe intrauterine adhesions. The human umbilical cord mesenchymal stem cell conditioned medium of the invention retains the efficacy of stem cell therapy and greatly reduces the risk of immunity and infection. 2 Under cross-linking, a gel will be formed at room temperature. Human umbilical cord mesenchymal stem cells can grow in this gel, thereby obtaining stem cell secretions, which significantly improves the therapeutic effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 The following are the pathological morphologies of the uterus in different experimental groups 28 days after intervention (HE staining, B, F, J, N, R, V, 40×; Masson staining, C, G, K, O, S, W, 40×, D, H, L, P, T, X, 200×).
[0018] Figure 2 These are the evaluation diagrams of IUA-related indicators in each group. A Endometrial thickness, B Endometrial gland count, C Fibrosis area percentage.
[0019] Figure 3 The results of immunohistochemical staining of fibrosis in each group. The expressions of collagen I, collagen III, Vimentin and α-SMA in the endometrium of each group 4 weeks after treatment (IHC, 200×).
[0020] Figure 4 These are the results of immunohistochemical staining of glandular epithelium in each group (IHC, 400×). DETAILED DESCRIPTION
[0021] The present invention is further described below in conjunction with examples. The following examples are only for illustration and are not intended to limit the scope of protection of the present invention in any way.
[0022] The processes and methods not described in detail in the following examples are all well-known methods in the art, and the reagents not described in detail in the present invention are all commercially available. 5 The culture fluid was obtained by culturing for 48 hours with a number of cells / mL.
[0023] Example 1
[0024] At room temperature, human umbilical cord mesenchymal stem cell conditioned medium, thrombin, aprotinin, CaCl 2 Mix well to make liquid A, and fibrinogen solution to make liquid B. When used, liquid A and liquid B are injected into the uterine cavity at the same time. The final concentrations of each component after mixing liquid A and liquid B are: fibrinogen 10 mg / mL, thrombin 1 U / mL, aprotinin 50 μg / mL, CaCl 2 40mmol / L, human umbilical cord mesenchymal stem cell conditioned medium 0.35mL / mL.
[0025] Example 2
[0026] At room temperature, human umbilical cord mesenchymal stem cell conditioned medium, thrombin, aprotinin, CaCl 2 Mix well to make liquid A, and fibrinogen solution to make liquid B. When used, liquid A and liquid B are injected into the uterine cavity at the same time. The final concentrations of each component after mixing liquid A and liquid B are: fibrinogen 10 mg / mL, thrombin 5 U / mL, aprotinin 250 μg / mL, CaCl 2 40mmol / L, human umbilical cord mesenchymal stem cell conditioned medium 0.30mL / mL.
[0027] Example 3
[0028] At room temperature, human umbilical cord mesenchymal stem cell conditioned medium, thrombin, aprotinin, CaCl 2 Mix well to make liquid A, and fibrinogen solution to make liquid B. When used, inject liquid A and liquid B into the uterine cavity at the same time. The final concentrations of each component after mixing liquid A and liquid B are: fibrinogen 10 mg / mL, thrombin 3 U / mL, aprotinin 150 μg / mL, CaCl 2 40mmol / L, human umbilical cord mesenchymal stem cell conditioned medium 0.40mL / mL.
[0029] Example 4
[0030] At room temperature, human umbilical cord mesenchymal stem cell conditioned medium, thrombin, aprotinin, CaCl 2Mix well to make liquid A, and fibrinogen solution to make liquid B. When used, liquid A and liquid B are injected into the uterine cavity at the same time. The final concentrations of each component after mixing liquid A and liquid B are: fibrinogen 8 mg / mL, thrombin 3 U / mL, aprotinin 150 μg / mL, CaCl 2 30mmol / L, human umbilical cord mesenchymal stem cell conditioned medium 0.35mL / mL.
[0031] Example 5
[0032] At room temperature, human umbilical cord mesenchymal stem cell conditioned medium, thrombin, aprotinin, CaCl 2 Mix well to make liquid A, and fibrinogen solution to make liquid B. When used, liquid A and liquid B are injected into the uterine cavity at the same time. The final concentrations of each component after mixing liquid A and liquid B are: fibrinogen 12 mg / mL, thrombin 3 U / mL, aprotinin 150 μg / mL, CaCl 2 50mmol / L, human umbilical cord mesenchymal stem cell conditioned medium 0.35mL / mL.
[0033] Example 6
[0034] Thirty-six female SD rats aged 10 to 12 weeks were divided into six groups, A, intrauterine adhesion group (IUA group), B, intraperitoneal injection of human umbilical cord mesenchymal stem cells group (peritoneal group), C, fibrin glue group, D, fibrin-human umbilical cord mesenchymal stem cell glue group (UCMSCs glue group), E, fibrin-human umbilical cord mesenchymal stem cell whole cell culture fluid glue group (UCMSCs-CM glue group), and F, normal group, with 6 rats in each group. The double injury method was used to create the model of intrauterine adhesion in groups A, B, C, D, and E. Two weeks later, group B was given 1×10 UCMSCs from P3 to P5. 6 (cell concentration was 1×10 6 / ml), and 1ml was injected intraperitoneally into each rat. Groups C, D, and E were given pure fibrin glue, UCMSCs glue, and UCMSCs-CM glue intrauterine injection, respectively. The components of liquid A and liquid B for preparing the above gels are shown in Table 1 (a total of 1ml was injected into the uterine cavity on both sides of each rat. During treatment, liquid A and liquid B were divided into two portions, and liquid B was fully shaken before application. The number of cells in the UCMSCs suspension was 1×10 6). Three rats in each group were killed one month after treatment, and a part of the samples was taken for HE staining, Masson staining, and immunohistochemical staining. The results of immunohistochemical staining were independently reviewed by two observers, and 5 fields of view were randomly selected under a 400x light microscope. The semi-quantitative integration method was used to make a comprehensive score based on the percentage of positive cells and the degree of staining in the cell membrane, cytoplasm, and epithelial cells. The scoring criteria for the percentage of positive cells were: no cell staining was 0 points, ≤25% was 1 point, 26% to 50% was 2 points, and >50% was 3 points. Staining intensity scoring: no cell staining was 0 points, light yellow was 1 point, brown was 2 points, and brown was 3 points. The score of each section was the sum of the percentage of positive cells and the degree of staining. 0 points were (-), 1 to 2 points were (+), 3 to 4 points were (++), 5 to 6 points were (+++), 0 to 2 points were negative, and 3 to 6 points were positive. The other 3 rats were subjected to the cage test two months after treatment. The experimental results are shown in the figure.
[0035] Table 1:
[0036]
[0037] Figure 1 The improvement of fibrosis degree in each group; Figure 2 Evaluation of IUA-related indicators for each group.
[0038] Endometrial thickness: There were statistical differences among the six groups (F=6.808, P=0.000). Further LSD method pairwise comparison showed that the IUA group had no statistical significance compared with the fibrin glue group, but had statistical significance compared with other groups, proving that the peritoneal group, UCMSCs glue and UCMSCs-CM glue were effective in restoring endometrial thickness after IUA. The peritoneal group had no statistical significance compared with the normal group, but had statistical significance compared with other treatment groups, proving that its thickness was closest to that of the normal group, and its treatment effect was better than that of other treatment groups from the perspective of endometrial thickness recovery (Fig.2A)
[0039] Endometrial gland number: There were statistical differences among the six groups (F=6.033, P=0.001). Further LSD method pairwise comparison showed that the IUA group had no statistical significance compared with the fibrin glue group and the UCMSCs-CM glue group, but had statistical significance compared with the other two groups, indicating that intraperitoneal injection of UCMSCs and intrauterine perfusion of UCMSCs glue were effective in restoring the number of glands after IUA. The normal group had statistical differences with the fibrin glue group, but no statistical differences with the UCMSCs-CM glue group, proving that the UCMSCs-CM glue group was inferior to the peritoneal group and the UCMSCs glue group in restoring the number of endometrial glands, but better than the fibrin glue group (Fig. 2B).
[0040] Percentage of fibrosis area: There were statistical differences among the six groups (F=31.866, P=0.000). Further LSD method pairwise comparison showed that the IUA group and the normal group were statistically significant compared with the four treatment groups, proving that intraperitoneal injection of UCMSCs, intrauterine perfusion of fibrin glue, UCMSCs glue and UCMSCs-CM glue groups all had therapeutic effects on the recovery of fibrosis after IUA. There was no statistical difference between the fibrin glue group and the UCMSCs-CM glue group; there was no statistical difference between the peritoneal group and the UCMSCs glue group; while the fibrin glue group and the UCMSCs-CM glue group were statistically different from the peritoneal group and the UCMSCs glue group, respectively, indicating that the peritoneal group and the UCMSCs glue group had better therapeutic effects on the recovery of endometrial fibrosis than the fibrin glue group and the UCMSCs-CM glue group (Fig. 2C).
[0041] Four weeks after treatment, the expressions of collagen I, Vimentin, and α-SMA, which are indicators of fibrosis in each group, are as follows (see Fig. 3):
[0042] Collagen I and Vimentin are mainly distributed in the endometrial stroma, and α-SMA is distributed in the endometrial stroma and myometrium. Collagen I is an important component of the extracellular matrix, and its expression increases with the degree of fibrosis. Vimentin is the main component of medium fibers (type II protein), plays a role as a cell scaffold in fibroblasts, and is also a marker of mesenchymal tissue. α-SMA is generally expressed in muscle cells. During fibrosis, fibroblasts can be transformed into myofibroblasts, thereby specifically expressing α-SMA. It can be seen in all groups that collagen I was positive (+~++) in the UCMSC-CM gel group and IUA group by semi-quantitative integration method in this study, and negative (+) in the other groups; Vimentin was negative (+) in the normal group and the simple gel group, and positive in the other groups, (++) in the peritoneal group, UCMSC gel group and UCMSC-CM gel group, and (+++) in the IUA group; α-SMA was negative (+) in all groups.
[0043] AE1 is mainly distributed in the endometrial epithelium and glandular epithelium and is a marker for epithelial cells. In this study, AE1 expression in all groups was positive (+++). (See Fig. 4).
[0044] Cage test (reproduction results)
[0045] Because the IUA, peritoneal group and UCMSC gel group did not meet the normal distribution, the Kruskal-Wallis test was required. The H value was 13.180, corresponding to a P value of 0.022, indicating that there were differences between the groups. In pairwise comparison, only the normal group and the IUA group showed a difference (Adj.p<0.05). Although the results of each treatment group were not statistically significant with those of the IUA group, the number of live births in each treatment group was better than that of the IUA group based on the data of variance ± standard deviation (Table 2).
[0046] Table 2: Number of live births in each group
[0047]
Claims
1. A fibrin-human umbilical cord mesenchymal stem cell conditioned medium gel for preparing a preparation for treating intrauterine adhesions, It is characterized in that Includes the following components: Fibrinogen 8-12 mg / mL, thrombin 1-5 U / mL, aprotinin 50-250 μg / mL, CaCl 2 30-50mmol / L, human umbilical cord mesenchymal stem cell conditioned medium 0.30-0.40 mL / mL; the preparation method of the gel is to mix human umbilical cord mesenchymal stem cell conditioned medium, thrombin, aprotinin and CaCl at room temperature 2 The mixture is uniformly mixed to form liquid A, and the fibrinogen solution is liquid B, and liquid A and liquid B are packaged separately; when used, liquid A and liquid B are injected into the uterine cavity at the same time; the human umbilical cord mesenchymal stem cell conditioned medium is human umbilical cord mesenchymal stem cells at a concentration of 2×10 5 ~8×10 5 The number of cells / mL is obtained by culturing the conditioned medium in mesenchymal stem cell serum-free medium for 46-50 hours.
2. The gel according to claim 1, It is characterized in that Includes the following components: fibrinogen 10 mg / mL, thrombin 1-5 U / mL, aprotinin 50-250 μg / mL, CaCl 2 40mmol / L, human umbilical cord mesenchymal stem cell conditioned medium 0.30-0.40 mL / mL.
3. The gel according to claim 1, It is characterized in that The culture medium used was: S&XFM mesenchymal stem cell serum-free medium.
4. A method for preparing a fibrin-human umbilical cord mesenchymal stem cell conditioned medium gel for preparing a preparation for treating intrauterine adhesions, It is characterized in that At room temperature, human umbilical cord mesenchymal stem cell conditioned medium, thrombin, aprotinin and CaCl 2 The mixture is uniformly mixed to form liquid A, and the fibrinogen solution is liquid B. Liquid A and liquid B are packaged separately. When used, liquid A and liquid B are injected into the uterine cavity at the same time. The final concentrations of the components of liquid A and liquid B after mixing are: fibrinogen 8-12 mg / mL, thrombin 1-5 U / mL, aprotinin 50-250 μg / mL, CaCl 2 30-50mmol / L, human umbilical cord mesenchymal stem cell conditioned medium 0.30-0.40 mL / mL; the human umbilical cord mesenchymal stem cell conditioned medium is human umbilical cord mesenchymal stem cells at 2×10 5 ~8×10 5 The number of cells / mL is obtained by culturing the conditioned medium in mesenchymal stem cell serum-free medium for 46-50 hours.
5. Use of the gel according to any one of claims 1 to 3 in preparing a preparation for treating intrauterine adhesions.
